azoxymethane has been researched along with metformin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chihara, T; Endo, H; Fujita, K; Hosono, K; Inamori, M; Nakagama, H; Nakajima, A; Nozaki, Y; Shimpo, K; Sugiyama, M; Suzuki, K; Takahashi, H; Tomatsu, A; Uchiyama, T; Yoneda, K; Yoneda, M | 1 |
| Asch, AS; Kumar, G; Lightfoot, S; Madka, V; Mohammed, A; Pathuri, G; Rao, CV; Steele, VE; Zhang, Y | 1 |
2 other study(ies) available for azoxymethane and metformin
| Article | Year |
|---|---|
Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Anticarcinogenic Agents; Apoptosis; Azoxymethane; Cell Proliferation; Colon; Colonic Polyps; Colorectal Neoplasms; Epithelial Cells; Hypoglycemic Agents; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Lipids; Metformin; Mice; Mice, Inbred BALB C; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases; TOR Serine-Threonine Kinases | 2010 |
Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model.
Topics: Administration, Oral; Alendronate; Animals; Anticarcinogenic Agents; Apoptosis; Azoxymethane; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Male; Metformin; Neoplasms, Experimental; Rats; Rats, Inbred F344; Zoledronic Acid | 2020 |